Shin Nippon Biomedical Laboratories, Ltd.

TSE:2395 Stock Report

Market Cap: JP¥69.8b

Shin Nippon Biomedical Laboratories Valuation

Is 2395 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2395 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2395 (¥1687) is trading above our estimate of fair value (¥293.98)

Significantly Below Fair Value: 2395 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2395?

Key metric: As 2395 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2395. This is calculated by dividing 2395's market cap by their current earnings.
What is 2395's PE Ratio?
PE Ratio18x
EarningsJP¥3.90b
Market CapJP¥69.82b

Price to Earnings Ratio vs Peers

How does 2395's PE Ratio compare to its peers?

The above table shows the PE ratio for 2395 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.7x
2309 CMIC HOLDINGS
8.4xn/aJP¥44.7b
4880 CellSource
67.5x23.9%JP¥16.3b
7079 WDB coco
8.8xn/aJP¥8.4b
4570 Immuno-Biological Laboratories
18xn/aJP¥4.2b
2395 Shin Nippon Biomedical Laboratories
18x14.4%JP¥69.8b

Price-To-Earnings vs Peers: 2395 is good value based on its Price-To-Earnings Ratio (18x) compared to the peer average (25.7x).

Price to Earnings Ratio vs Industry

How does 2395's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
2395 18.0xIndustry Avg. 33.8xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2395 is good value based on its Price-To-Earnings Ratio (18x) compared to the Asian Life Sciences industry average (33.8x).

Price to Earnings Ratio vs Fair Ratio

What is 2395's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2395 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18x
Fair PE Ratio19.1x

Price-To-Earnings vs Fair Ratio: 2395 is good value based on its Price-To-Earnings Ratio (18x) compared to the estimated Fair Price-To-Earnings Ratio (19.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2395 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,687.00
JP¥2,530.00
+50.0%
42.3%JP¥3,600.00JP¥1,460.00n/a2
Oct ’25JP¥1,224.00
JP¥1,340.00
+9.5%
11.9%JP¥1,500.00JP¥1,180.00n/a2
Sep ’25JP¥1,208.00
JP¥1,340.00
+10.9%
11.9%JP¥1,500.00JP¥1,180.00n/a2
Aug ’25JP¥1,222.00
JP¥1,450.00
+18.7%
3.4%JP¥1,500.00JP¥1,400.00n/a2
May ’25JP¥1,542.00
JP¥3,150.00
+104.3%
11.1%JP¥3,500.00JP¥2,800.00n/a2
Apr ’25JP¥1,503.00
JP¥3,150.00
+109.6%
11.1%JP¥3,500.00JP¥2,800.00n/a2
Mar ’25JP¥1,621.00
JP¥3,650.00
+125.2%
23.3%JP¥4,500.00JP¥2,800.00n/a2
Feb ’25JP¥1,703.00
JP¥3,650.00
+114.3%
23.3%JP¥4,500.00JP¥2,800.00n/a2
Jan ’25JP¥1,698.00
JP¥3,650.00
+115.0%
23.3%JP¥4,500.00JP¥2,800.00n/a2
Dec ’24JP¥1,642.00
JP¥3,650.00
+122.3%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,597.002
Nov ’24JP¥1,695.00
JP¥3,650.00
+115.3%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,221.002
Oct ’24JP¥1,872.00
JP¥3,650.00
+95.0%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,224.002
Sep ’24JP¥2,226.00
JP¥3,650.00
+64.0%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,208.002
Aug ’24JP¥2,117.00
JP¥3,650.00
+72.4%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,222.002
Jul ’24JP¥2,130.00
JP¥3,650.00
+71.4%
23.3%JP¥4,500.00JP¥2,800.00JP¥1,395.002
Jun ’24JP¥2,400.00
JP¥3,700.00
+54.2%
18.9%JP¥4,500.00JP¥2,800.00JP¥1,358.003
May ’24JP¥2,518.00
JP¥3,600.00
+43.0%
26.2%JP¥4,500.00JP¥2,300.00JP¥1,542.003
Apr ’24JP¥2,750.00
JP¥4,400.00
+60.0%
13.6%JP¥5,000.00JP¥3,800.00JP¥1,503.002
Mar ’24JP¥2,777.00
JP¥4,400.00
+58.4%
13.6%JP¥5,000.00JP¥3,800.00JP¥1,621.002
Feb ’24JP¥2,189.00
JP¥4,200.00
+91.9%
9.5%JP¥4,600.00JP¥3,800.00JP¥1,703.002
Jan ’24JP¥2,260.00
JP¥4,200.00
+85.8%
9.5%JP¥4,600.00JP¥3,800.00JP¥1,698.002
Dec ’23JP¥2,712.00
JP¥4,200.00
+54.9%
9.5%JP¥4,600.00JP¥3,800.00JP¥1,642.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:49
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuki TsukamotoBofA Global Research
Akitada IwasaDaiwa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.